EMERpharma Ltd logo

EMERpharma Ltd

EMERpharma Ltd (EMER) is a clinical stage pharmaceutical company, focuses on cognition disorders and addiction disorders with ADHD and cocaine addiction as lead indications.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.nhtherapeutics.com
Founded2012
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
MaRS, 661 University Ave, Suite 800, ON, M5G 1M1
Toronto
Canada
Email
Contact Number
+1 415548 8058

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/emerpharma” connections=”true” suffix=””]

In Oct 2014, EMERpharma acquired an exclusive license to develop ASP2905/EM902 from Astellas Inc., mainly for the treatment of ADHD (attention deficit hyperactivity disorder) as well as other psychiatric indications.

EMERpharma is currently seeking USD $40 Mn to bring EM902 to market for the treatment of Huntingtons disease.